Rithish Nimmagadda

Dr. Rithish Nimmagadda

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JUJahnavi Udaikumar
Jahnavi Udaikumar
RNRithish Nimmagadda
Rithish Nimmagadda
VLVindhya vasini Lella
Vindhya vasini Lella
KAKesava Manikanta Achuta
Kesava Manikanta Achuta
SKSatwik Kuppili
Satwik Kuppili
RSRaiya Sarwar
Raiya Sarwar
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have emerged as promising agents targeting distinct metabolic and inflammatory pathways. This systematic review compares the safety and efficacy of resmetirom and semaglutide in MASLD. Methods: We conducted a comprehensive search of PubMed, Embase, and Google Scholar for randomized controlled trials and clinical studies published between January 2014 and April 2025, following PRISMA guidelines. Studies assessing the efficacy and safety of resmetirom and/or semaglutide in MASLD or NASH were included. Data extraction was performed by two independent reviewers, and a narrative synthesis was undertaken due to the heterogeneity in study design and outcome measures. Results: Fourteen studies encompassing over 4500 patients were analyzed. Resmetirom demonstrated consistent reductions in hepatic fat (≥30% in >50% of patients) and improvements in fibrosis (≥1 stage in up to 26.4% of patients), as evidenced in the MAESTRO-NASH trial. Semaglutide achieved higher rates of NASH resolution (up to 62.9%) without worsening fibrosis, especially among patients with type 2 diabetes or obesity, although fibrosis improvement was less consistently observed. Resmetirom was well tolerated with low discontinuation rates, while semaglutide was associated with more frequent, yet manageable, gastrointestinal adverse events. Conclusions: Both resmetirom and semaglutide show therapeutic potential for MASLD. Resmetirom offers more consistent antifibrotic effects, while semaglutide excels in NASH resolution and metabolic improvement. The absence of direct comparative trials underscores the need for future head-to-head studies to guide tailored treatment strategies in MASLD management.

2 June 2025 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
JUJahnavi Udaikumar
Jahnavi Udaikumar
RNRithish Nimmagadda
Rithish Nimmagadda
SISushrut Ingawale
Sushrut Ingawale
VLVindhya vasini Lella
Vindhya vasini Lella
KVKeerthika Vijayakumar
Keerthika Vijayakumar
ASAasma Shaukat
Aasma Shaukat

9 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SKSreeja Koundinya
Sreeja Koundinya
RCRumitha Chakilam
Rumitha Chakilam
GBGayatri Brahmandam
Gayatri Brahmandam
LELina Elkadri
Lina Elkadri
SASajjad Ghanim Al-Badri
Sajjad Ghanim Al-Badri
RNRithish Nimmagadda
Rithish Nimmagadda
Background: Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, yet concerns about their long-term effects on cognitive function persist. Emerging evidence suggests a possible association between prolonged PPI use and increased dementia risk, though findings remain inconclusive. This narrative review focuses on pantoprazole, a PPI with unique pharmacokinetics, to assess its potential role in dementia development. Methods: A systematic search was conducted using PubMed and PubMed Central with keywords including “dementia,” “proton pump inhibitors,” “Alzheimer’s disease,” and “adverse effects of PPIs,” etc. Studies published from 1 January 2002 to 31 December 2024 were included, focusing on clinical trials, cohort studies, meta-analyses, and systematic reviews. Two independent reviewers assessed eligibility by screening abstracts and full texts, excluding case reports, conference abstracts, and editorial letters. Results: Thirteen studies investigating the association between PPI use and dementia were included. Observational studies in Asian populations reported an increased risk, whereas Western studies showed inconsistent results. Mechanistic insights suggest PPIs may contribute to dementia through amyloid-β accumulation, vitamin B12 deficiency, and endothelial dysfunction. Mendelian randomization studies and meta-analyses found no statistically significant association. Pantoprazole’s prolonged acid suppression may differentially influence dementia risk. Conclusion: Evidence on the link between long-term PPI use and dementia is conflicting, with variability in study populations and methodological limitations. Further prospective studies and randomized controlled trials are needed to clarify causality. Clinicians should exercise caution, reassess long-term PPI necessity, and consider alternatives to mitigate potential risks.

30 March 2026 in Digestive Diseases
Verified
Journal Article
Open access
YGYashaswi Guntupalli
Yashaswi Guntupalli
RNRithish Nimmagadda
Rithish Nimmagadda
VPVineeth Potluri
Vineeth Potluri
SMSameer Kumar Majety
Sameer Kumar Majety
TMTejaswi Mangalagiri
Tejaswi Mangalagiri
MHMuhammad Hasan
Muhammad Hasan
Introduction: Circulating tumor DNA (ctDNA) assays are emerging as promising noninvasive tools for colorectal cancer (CRC) screening. This updated systematic review and meta-analysis evaluated the diagnostic accuracy of blood-based ctDNA assays for early CRC detection in asymptomatic adults. Methods: We included prospective and cross-sectional diagnostic accuracy studies comparing ctDNA assays (mutation, methylation, or fragment-based) against colonoscopy or histopathology. Study-level 2 × 2 data were extracted to calculate sensitivity and specificity. Pooled estimates were derived using a Reitsma bivariate random-effects model. Secondary measures like diagnostic odds ratio (DOR), positive and negative likelihood ratios (PLR, NLR), positive predictive value (PPV), and negative predictive value (NPV) were synthesized on transformed scales and back-transformed for reporting. Subgroup analyses by assay type and meta-regression explored heterogeneity. Risk of bias was assessed with QUADAS-2 and certainty of evidence with GRADE. Results: Ten studies met inclusion criteria, nine contributing to pooled estimates. The pooled sensitivity was 0.887 (95% CI, 0.848–0.920) and specificity 0.913 (95% CI, 0.898–0.928). A sensitivity analysis excluding studies with high risk of bias in patient selection yielded a comparable pooled sensitivity of 0.857 (95% CI, 0.794–0.904) and specificity of 0.900 (95% CI, 0.897–0.904). The SROC curve yielded an AUC of 0.97, indicating excellent discrimination. Secondary pooled metrics included a DOR of 83.9, PLR of 9.2, and NLR of 0.12. PPV was low (99%) at screening prevalences of 0.5–2%. Subgroup analyses by assay type revealed no significant differences in diagnostic accuracy. Conclusion: Blood-based ctDNA assays show high pooled sensitivity, specificity, and discrimination for CRC detection, but limited predictive value at screening prevalence and study heterogeneity constrain clinical adoption. Large, standardized, population-based studies are warranted.

5 January 2026 in Journal For International Medical Graduates
Verified
Journal Article
Open access
PDF file
BSBushra firdous Shaik
Bushra firdous Shaik
EEExcel Ernest-Okonofua
Excel Ernest-Okonofua
OMOmar Ahmed Mohammed Sami Mahroq
Omar Ahmed Mohammed Sami Mahroq
SGShakirat Oyindolapo Ganiyu
Shakirat Oyindolapo Ganiyu
RNRithish Nimmagadda
Rithish Nimmagadda
MNMarcellina Nwosu
Marcellina Nwosu
Sickle cell disease (SCD) is a chronic, inherited blood disorder marked by the presence of abnormal hemoglobin, which causes red blood cells to assume a rigid, sickle-like shape. These distorted cells contribute to hemolysis, impaired blood flow, and recurrent vaso-occlusive crises (VOCs), the hallmark and most debilitating complication of the disease. Beyond acute pain episodes, Sickle cell disease leads to progressive organ damage and reduced life expectancy, placing a substantial burden on patients and healthcare systems worldwide. While supportive care has long been the cornerstone of management, the emergence of targeted therapies offers new hope. Crizanlizumab, a humanized monoclonal antibody directed against P-selectin, disrupts the cellular adhesion processes that drive vaso-occlusive crises. This review highlights the pathophysiology of Sickle cell disease, details the mechanism of action of crizanlizumab, and evaluates clinical trial evidence regarding its efficacy, safety, and therapeutic potential. Collectively, the findings underscore crizanlizumab’s promise as a transformative therapy that can reduce VOC frequency and improve quality of life for individuals living with SCD.

18 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Akshay KumarAkshay Kumar
Akshay Kumar
NCNicole Carlo
Nicole Carlo
RNRithish Nimmagadda
Rithish Nimmagadda
JSJuber Dastagir Shaikh
Juber Dastagir Shaikh
SKSourabh Khatri
Sourabh Khatri
VVVivek Varghese
Vivek Varghese
Background: Unfractionated heparin (UFH) remains the standard anticoagulant for extracorporeal membrane oxygenation (ECMO), despite complications, such as heparin resistance, heparin-induced thrombocytopenia, bleeding and variable pharmacokinetics. This has prompted the search for alternative and novel anticoagulation strategies, including pharmacologic agents, circuit modifications, and monitoring approaches. This scoping review aimed to map the breadth and characteristics of evidence on ECMO anticoagulation strategies beyond UFH. Methods: A comprehensive search of peer-reviewed and gray literature was conducted across PubMed, Cochrane, Clinical Trials, WHO Trials Registry, and conference abstracts through manual searches in key journals. Clinical, pre-clinical, and gray literature studies evaluating pharmacologic agents, anticoagulation-free or heparin-sparing, biocompatible circuits, and monitoring innovations were included. Data were charted and synthesized descriptively to identify trends, gaps, and emerging directions. Results: A total of 269 records were included. Evidence was highly heterogeneous among study designs, populations, ECMO modalities, and outcome definitions. Most clinical studies were retrospective cohorts and adult-centered, with limited multicenter randomized controlled trials and underrepresentation of neonatal and pediatric populations. Direct thrombin inhibitors were frequently studied and clinically implemented alternatives to UFH. Other agents, including nafamostat mesylate, prostaglandin E1, and factor pathway inhibitors remain early in clinical investigation. Anticoagulation-free strategies and biocompatible circuit technologies were mostly supported through pre-clinical and single-center studies. Monitoring and modeling innovations, like TEG, ROTEM, real-time imaging, and machine learning, are quickly emerging. Conclusions: ECMO anticoagulation is transitioning from UFH reliance toward diversified and personalized strategies. Future research should prioritize multicenter randomized controlled trials, standardize protocols, expand to neonatal and pediatric investigation, and integrate strategies.